XML 38 R54.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Collaboration and License Agreements - Additional Information 5 (Detail) (USD $) | 1 Months Ended | 12 Months Ended
--- | --- | ---
Oct. 31, 2010 Molecule | Dec. 31, 2014 Program | Dec. 31, 2013 | Dec. 31, 2012
License And Collaboration Agreements [Line Items] |  |  |  |
Deferred revenue |  | $ 14,248,000 us-gaap_DeferredRevenueCurrent | $ 20,267,000 us-gaap_DeferredRevenueCurrent |
Pfizer [Member] |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |
Collaboration agreement date |  | October 2010 |  |
Period of agreement |  | 3 years |  |
Commercialization of molecules | 2 mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember |  |  |
Nonrefundable upfront payment | 5,000,000 mgnx_NonRefundableUpFrontPayment / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember | 5,000,000 mgnx_NonRefundableUpFrontPayment / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember |  |
Clinical milestone payments |  | 17,000,000 mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember |  |
Commercialization and sales milestones |  | 195,000,000 mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember |  |
DART program |  | 1 mgnx_NumberOfPrograms / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember |  |
Research obligation completion date |  | 2014-01 |  |
Term of the agreement |  | 2014-01 |  |
Recognized revenue under agreement |  | 100,000 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember | 3,500,000 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember | 5,500,000 us-gaap_LicensesRevenue / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember
Milestones achieved |  | 0 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember |  | 500,000 us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember
Deferred revenue |  | $ 0 us-gaap_DeferredRevenueCurrent / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember | $ 7,000 us-gaap_DeferredRevenueCurrent / us-gaap_CounterpartyNameAxis = mgnx_PfizerIncMember |

X
- Definition Aggregate potential clinical milestone payments available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate potential remaining commercialization and sales milestone payments available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalPotentialCommercializationAndSalesMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration and license agreement entered date. + References No definition available. + Details
Name: | mgnx_CollaborationAndLicenseAgreementEnteredDate
Namespace Prefix: | mgnx_
Data Type: | us-types:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative agreement period of contract. + References No definition available. + Details
Name: | mgnx_CollaborativeAgreementPeriodOfContract
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | mgnx_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | mgnx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non-refundable up front payment. + References No definition available. + Details
Name: | mgnx_NonRefundableUpFrontPayment
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of molecules to be developed and commercialized as per collaborations. + References No definition available. + Details
Name: | mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of programs being pursued under collaboration agreement. + References No definition available. + Details
Name: | mgnx_NumberOfPrograms
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Research obligation completion date. + References No definition available. + Details
Name: | mgnx_ResearchObligationCompletionDate
Namespace Prefix: | mgnx_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront fee and participation recognition end date. + References No definition available. + Details
Name: | mgnx_UpfrontFeeAndParticipationRecognitionEndDate
Namespace Prefix: | mgnx_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_CounterpartyNameAxis=mgnx_PfizerIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |